The prognostic and potentially predictive value of the Laurén classification in oesophageal adenocarcinoma.

AIM To investigate the histological subtypes of oesophageal adenocarcinoma according to the Laurén classification (intestinal/diffuse/mixed) in relation to tumour response to neoadjuvant treatment, and in relation to patients' survival after potentially curative treatment. METHODS Data were collected from all oesophageal adenocarcinoma patients who underwent potentially curative treatment in our institute between 1998 and 2014. Treatment consisted of neoadjuvant chemoradiotherapy (36-50 Gy) followed by an oesophagectomy or definitive chemoradiotherapy (50-50.4 Gy). Clinical data were collected from patient records. All endoscopic biopsies and surgical resection specimens were reassessed to determine the histological subtype (intestinal, diffuse or mixed) and the Mandard tumour regression grade (TRG). The impact of the histological subtypes on survival was determined using a Cox model. RESULTS Median follow-up was 68 months. Diffuse and mixed type cancers accounted for 25% of oesophageal adenocarcinomas. Median overall survival differed significantly between patients with intestinal (n = 121, 39 months), diffuse (n = 28, 18 months) or mixed type (n = 11, 25 months) carcinomas (log rank, p = 0.023). In multivariable analysis, the diffuse type was associated with shorter survival (diffuse versus intestinal: hazard ratios 2.06, p = 0.006). A pathologically (near) complete response (TRG 1 or 2) was seen less frequently in diffuse type than in intestinal type carcinomas (24% versus 60%; p = 0.015). CONCLUSIONS Patients with diffuse type oesophageal adenocarcinomas had a significantly worse prognosis than those with intestinal type carcinomas. Intestinal type carcinomas showed a better response to neoadjuvant chemoradiotherapy than diffuse type carcinomas. These differences call for the exploration of differentiated approaches in the potentially curative treatment of oesophageal adenocarcinomas.

[1]  Sabine Siesling,et al.  Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. , 2008, European journal of cancer.

[2]  J. Paul,et al.  Oesophageal and gastric intestinal-type adenocarcinomas show the same male predominance due to a 17 year delayed development in females , 2008, Gut.

[3]  Eugene H. Blackstone,et al.  7th Edition of the AJCC Cancer Staging Manual: Esophagus and Esophagogastric Junction , 2010, Annals of Surgical Oncology.

[4]  H. Höfler,et al.  Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy , 2003, Cancer.

[5]  W. Mellin,et al.  Adenocarcinomas of esophagus and cardia in comparison with gastric carcinoma , 2005, Journal of Cancer Research and Clinical Oncology.

[6]  C. Reed,et al.  Adenocarcinoma of the esophagus with signet ring cell features portends a poor prognosis. , 2013, The Annals of thoracic surgery.

[7]  J. Ajani,et al.  Signet-Ring Cell or Mucinous Histology after Preoperative Chemoradiation and Survival in Patients with Esophageal or Esophagogastric Junction Adenocarcinoma , 2005, Clinical Cancer Research.

[8]  F. Roviello,et al.  Different Patterns of Recurrence in Gastric Cancer Depending on Lauren’s Histological Type: Longitudinal Study , 2002, World Journal of Surgery.

[9]  Simon Tavaré,et al.  Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance , 2016, Nature Genetics.

[10]  A. Hölscher,et al.  Differences between Biopsy- or Specimen-related Laurén andWorld Health Organization Classification in Gastric Cancer , 2002, World Journal of Surgery.

[11]  E. Bollschweiler,et al.  Pathohistological classification systems in gastric cancer: diagnostic relevance and prognostic value. , 2014, World journal of gastroenterology.

[12]  J. Coebergh,et al.  Increased incidence and survival for oesophageal cancer but not for gastric cardia cancer in the Netherlands. , 2012, European journal of cancer.

[13]  E W Steyerberg,et al.  Preoperative chemoradiotherapy for esophageal or junctional cancer. , 2012, The New England journal of medicine.

[14]  F. Bosman,et al.  WHO Classification of Tumours of the Digestive System , 2010 .

[15]  R. Langer,et al.  Tumor Regression Grading of Gastrointestinal Carcinomas after Neoadjuvant Treatment , 2013, Front. Oncol..

[16]  A. Bass,et al.  Oesophageal adenocarcinoma and gastric cancer: should we mind the gap? , 2016, Nature Reviews Cancer.

[17]  Yoon-Koo Kang,et al.  Postoperative Nodal Status and Diffuse-type Histology Are Independent Prognostic Factors in Resectable Advanced Gastric Carcinomas After Preoperative Chemotherapy , 2013, The American journal of surgical pathology.

[18]  M. Sarbia The histological appearance of oesophageal adenocarcinoma—an analysis based on 215 resection specimens , 2006, Virchows Archiv.

[19]  M. Hauptmann,et al.  Surgical treatment results of intestinal and diffuse type gastric cancer. Implications for a differentiated therapeutic approach? , 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[20]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[21]  K. Becker,et al.  Prognostic value of DNA ploidy and cerbB‐2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus , 1994, Cancer.

[22]  S. Devesa,et al.  Stomach Carcinoma Incidence Patterns in the United States by Histologic Type and Anatomic Site , 2009, Cancer Epidemiology Biomarkers & Prevention.

[23]  F. Roviello,et al.  Prospective study of peritoneal recurrence after curative surgery for gastric cancer , 2003, The British journal of surgery.

[24]  J. Petiot,et al.  Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations , 1994, Cancer.

[25]  C. Clarke,et al.  Long-term survivors of gastric cancer: a California population-based study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  V. Moreno,et al.  Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973–1995 , 2002, International journal of cancer.

[27]  A. Malik,et al.  Optimal number of biopsy specimens in the diagnosis of carcinoma of the oesophagus. , 1992, Gut.

[28]  F. Paraf,et al.  Expression of c-erbB-2 oncogene product in Barrett's adenocarcinoma: pathological and prognostic correlations. , 1994, Journal of clinical pathology.

[29]  J. V. van Sandick,et al.  Prognostic Value of Laurén Classification and c-erbB-2 Oncogene Overexpression in Adenocarcinoma of the Esophagus and Gastroesophageal Junction , 1999, Annals of Surgical Oncology.

[30]  V. Gebski,et al.  Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. , 2011, The Lancet. Oncology.

[31]  J. Ajani,et al.  Signet ring cells in esophageal adenocarcinoma predict poor response to preoperative chemoradiation. , 2014, The Annals of thoracic surgery.

[32]  C. Mariette,et al.  The impact of preoperative radiochemotherapy on survival in advanced esophagogastric junction signet ring cell adenocarcinoma. , 2014, The Annals of thoracic surgery.

[33]  M. Bains,et al.  Patterns of Initial Recurrence in Completely Resected Gastric Adenocarcinoma , 2004, Annals of surgery.

[34]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.

[35]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[36]  P. Laurén,et al.  THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. , 1965, Acta pathologica et microbiologica Scandinavica.

[37]  R. Langer,et al.  Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas , 2014, British Journal of Cancer.